Management of Sertraline (Zoloft) and Quetiapine (Seroquel) in Acute Kidney Injury
Do not routinely stop sertraline (Zoloft) in AKI, but strongly consider discontinuing quetiapine (Seroquel) due to its established nephrotoxicity and increased risk of worsening kidney injury.
Sertraline (Zoloft) - Continue with Monitoring
Sertraline does not require dose adjustment or discontinuation in AKI. According to the FDA drug label, "no dose adjustment is needed in patients with mild to severe renal impairment. Sertraline exposure does not appear to be affected by renal impairment" 1. This is a critical distinction—sertraline is primarily hepatically metabolized and is not nephrotoxic.
Key Considerations for Sertraline:
- Not a nephrotoxin: Sertraline does not cause direct kidney injury and is not eliminated renally
- Risk-benefit favors continuation: Abruptly stopping an SSRI in AKI risks psychiatric decompensation, which could worsen overall morbidity and mortality
- Monitor for complications: While sertraline itself is safe in AKI, watch for hyponatremia (SSRIs increase this risk, especially in elderly patients) and serotonin syndrome if combined with other serotonergic agents 1
- AKI may alter drug metabolism: AKI can impair cytochrome P450 activity and affect drug distribution through changes in protein binding and metabolic acidosis 2, potentially leading to slightly increased sertraline levels, though this is rarely clinically significant
When to Consider Stopping Sertraline:
Apply the ADQI guideline framework 2:
- If sertraline is deemed non-essential (e.g., recently started for mild symptoms)
- If a causal relationship exists between sertraline and the AKI (extremely rare—would require evidence of rhabdomyolysis 3 or severe hyponatremia causing prerenal AKI)
- If the patient develops serotonin syndrome contributing to rhabdomyolysis and AKI
Quetiapine (Seroquel) - Strongly Consider Discontinuation
Quetiapine should be discontinued in AKI unless it is absolutely essential for life-threatening psychiatric symptoms. The evidence demonstrates that atypical antipsychotics, particularly quetiapine, are associated with significant nephrotoxicity.
Evidence for Quetiapine Nephrotoxicity:
Quetiapine carries the highest risk of renal impairment among atypical antipsychotics 4. Multiple high-quality studies demonstrate:
- Increased AKI risk: Atypical antipsychotic use is associated with a 73% increased risk of hospitalization with AKI (RR 1.73,95% CI 1.55-1.92) 5
- Quetiapine-specific risk: In subgroup analysis, quetiapine showed elevated but non-significant AKI risk at 90 days (aHR 1.62,95% CI 0.81-3.26) 6, and a meta-analysis confirmed quetiapine carries the highest overall renal impairment risk among atypical antipsychotics 4
- Mechanism of injury: Quetiapine causes AKI through multiple pathways including hypotension, acute urinary retention, rhabdomyolysis, and myoglobin cast nephropathy 5, 7
- Long-term kidney damage: Beyond AKI, quetiapine is associated with increased risk of chronic kidney disease (RR 1.23,95% CI 1.12-1.35) 4
Applying ADQI Nephrotoxin Management Guidelines:
The ADQI consensus guidelines 2 provide clear criteria for discontinuing nephrotoxins in AKI:
Discontinue a nephrotoxin when:
- The drug is a potential cause of AKI (quetiapine meets this criterion)
- A less nephrotoxic alternative is available (consider switching to risperidone if antipsychotic is essential—risperidone showed no AKI association with aHR 0.68 6)
- The drug is non-essential (many quetiapine prescriptions are for off-label indications like insomnia or anxiety where safer alternatives exist)
Decision Algorithm for Quetiapine:
If quetiapine is essential (active psychosis, severe bipolar mania):
- Continue with intensive monitoring
- Ensure adequate hydration to prevent hypotension and prerenal AKI
- Monitor for urinary retention (check post-void residuals)
- Check CPK levels to detect early rhabdomyolysis
- Consider dose reduction if feasible
If quetiapine is non-essential (insomnia, mild anxiety, agitation):
- Discontinue immediately
- Substitute with non-nephrotoxic alternatives (trazodone for insomnia, benzodiazepines for acute agitation if needed short-term)
If switching antipsychotics is possible:
- Transition to risperidone, which showed no AKI association in the largest cohort study 6
- Avoid olanzapine, which has the highest AKI risk (aHR 3.50,95% CI 1.20-10.23) 6
Common Pitfalls to Avoid
Do not reflexively stop all psychiatric medications in AKI: This outdated practice can cause more harm than the medications themselves. Apply the ADQI framework systematically 2, 8
Do not confuse renal elimination with nephrotoxicity: Sertraline is not renally eliminated and does not cause kidney injury—there is no reason to stop it 1
Do not ignore the mechanism of AKI with quetiapine: If the patient has hypotension, urinary retention, or rhabdomyolysis, quetiapine is likely contributing and must be stopped 5, 7
Do not forget that AKI alters drug metabolism beyond renal clearance: AKI impairs hepatic cytochrome P450 activity, affecting both sertraline and quetiapine metabolism 2. This means drug levels may rise even for hepatically-cleared medications, requiring vigilance for toxicity
Monitor for secondary complications: Both drugs can contribute to falls, fractures, and delirium in AKI patients 9, which independently worsen mortality
Monitoring Strategy
For patients continuing either medication:
- Daily assessment of mental status and volume status
- Monitor serum creatinine and electrolytes (especially sodium with sertraline)
- For quetiapine: check CPK if rhabdomyolysis suspected, assess for urinary retention, monitor blood pressure
- Reassess medication necessity daily as AKI evolves
- Plan for medication restart or adjustment once kidney function stabilizes (GFR stabilized, volume status optimized) 2